{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:23:00Z","timestamp":1793380980253,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T00:00:00Z","timestamp":1613260800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T00:00:00Z","timestamp":1613260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Euglycemic diabetic ketoacidosis is an uncommon but life-threatening complication associated with the use of sodium-glucose cotransporter\u00a02 inhibitors that causes lower than expected blood glucose levels typically seen in diabetic ketoacidosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We present a case of 64-year-old Caucasian male patient previously diagnosed with type\u00a02 diabetes treated with a sodium-glucose cotransporter\u00a02 inhibitor who developed severe ketoacidosis. Serum glucose levels on initial presentation were slightly above normal baseline level. The patient was revealed to have latent autoimmune diabetes in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights the importance of prescribing sodium-glucose cotransporter\u00a02 inhibitors to the correct patient population and the significance of accurately differentiating between various types of diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13256-020-02607-2","type":"journal-article","created":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T04:47:47Z","timestamp":1613278067000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Sodium-glucose cotransporter-2-induced euglycemic diabetic ketoacidosis unmasks latent autoimmune diabetes in a patient misdiagnosed with type\u00a02 diabetes mellitus: a case report"],"prefix":"10.1186","volume":"15","author":[{"given":"Brian","family":"Vadasz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattan","family":"Arazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3353-5883","authenticated-orcid":false,"given":"Yousef","family":"Shukha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8666-8276","authenticated-orcid":false,"given":"Ofir","family":"Koren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad","family":"Taher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,14]]},"reference":[{"key":"2607_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/1479164114561992","volume":"12","author":"LA Gallo","year":"2015","unstructured":"Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diabetes Vasc Dis Res. 2015;12:78\u201389.","journal-title":"Diabetes Vasc Dis Res"},{"key":"2607_CR2","unstructured":"FDA. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. FDA Drug Saf Commun. 2015;2\u20134."},{"key":"2607_CR3","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.diabres.2013.12.052","volume":"103","author":"S Geerlings","year":"2014","unstructured":"Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract. 2014;103:373\u201381.","journal-title":"Diabetes Res Clin Pract"},{"key":"2607_CR4","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2016","unstructured":"Zinman B, Christoph W, Lachin JM, Fitchett D, Bluhmki E. Empagliflozin, cardiovascular outcomes, and mortality in type\u00a02 diabetes. N Engl J Med. 2016;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"2607_CR5","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"DZI Cherney","year":"2013","unstructured":"Cherney DZI, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2013;129:587\u201397.","journal-title":"Circulation"},{"key":"2607_CR6","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type\u00a02 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"2607_CR7","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00125-017-4301-8","volume":"60","author":"GP Fadini","year":"2017","unstructured":"Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA adverse event reporting system. Diabetologia. 2017;60:1385\u20139.","journal-title":"Diabetologia"},{"key":"2607_CR8","doi-asserted-by":"publisher","first-page":"753","DOI":"10.4158\/EP161292.PS","volume":"22","author":"Y Handelsman","year":"2016","unstructured":"Handelsman Y, Henry RR, Bloomgarden ZT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract. 2016;22:753\u201362.","journal-title":"Endocr Pract"},{"key":"2607_CR9","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.2337\/dc13-2338","volume":"37","author":"BA Perkins","year":"2014","unstructured":"Perkins BA, Tschirhart H, Cherney DZI, Partridge H, Soleymanlou N. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care. 2014;37:1480\u20133.","journal-title":"Diabetes Care"},{"issue":"604","key":"2607_CR10","first-page":"e3","volume":"33","author":"RS Hilaire","year":"2015","unstructured":"Hilaire RS, Costello H. Prescriber beware: report of adverse effect of sodium-glucose cotransporter 2 inhibitor use in a patient with contraindication. Am J Emerg Med. 2015;33(604):e3-604.e4.","journal-title":"Am J Emerg Med"},{"key":"2607_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/dmrr.2886","volume":"33","author":"H Qiu","year":"2017","unstructured":"Qiu H, Novikov A, Vallon V. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives. Diabetes Metab Res Rev. 2017;33:1\u20139.","journal-title":"Diabetes Metab Res Rev"},{"key":"2607_CR12","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s12020-017-1264-y","volume":"56","author":"A Pf\u00fctzner","year":"2017","unstructured":"Pf\u00fctzner A, Klonoff D, Heinemann L, Ejskjaer N, Pickup J. Euglycemic ketosis in patients with type\u00a02 diabetes on SGLT2-inhibitor therapy\u2014an emerging problem and solutions offered by diabetes technology. Endocrine. 2017;56:212\u20136.","journal-title":"Endocrine"},{"key":"2607_CR13","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.2337\/dc15-0843","volume":"38","author":"AL Peters","year":"2015","unstructured":"Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1687\u201393.","journal-title":"Diabetes Care"},{"key":"2607_CR14","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.amjmed.2017.09.014","volume":"131","author":"T Nodzynski","year":"2018","unstructured":"Nodzynski T, Lee TC. A rose by any other name: ketoacidosis due to SGLT2 inhibitors reveals latent autoimmune diabetes. Am J Med. 2018;131:e1\u20133.","journal-title":"Am J Med"},{"key":"2607_CR15","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1016\/j.clinthera.2016.11.002","volume":"38","author":"RM Goldenberg","year":"2016","unstructured":"Goldenberg RM, Berard LD, Cheng AYY, et al. SGLT2 inhibitor\u2013associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther. 2016;38:2654-2664.e1.","journal-title":"Clin Ther"},{"key":"2607_CR16","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1210\/jc.2015-1884","volume":"100","author":"SI Taylor","year":"2015","unstructured":"Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100:2849\u201352.","journal-title":"J Clin Endocrinol Metab"},{"key":"2607_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/phar.1881","volume":"37","author":"KR Burke","year":"2017","unstructured":"Burke KR, Schumacher CA, Harpe SE. SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature. Pharmacotherapy. 2017;37:187\u201394.","journal-title":"Pharmacotherapy"},{"key":"2607_CR18","doi-asserted-by":"publisher","first-page":"e2924","DOI":"10.1002\/dmrr.2924","volume":"33","author":"JE Blau","year":"2017","unstructured":"Blau JE, Tella SH, Taylor SI, Rother KI. Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data. Diabetes Meta Res Rev. 2017;33:e2924.","journal-title":"Diabetes Meta Res Rev"},{"key":"2607_CR19","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type\u00a02 diabetic patients. J Clin Invest. 2014;124:499\u2013508.","journal-title":"J Clin Invest"},{"key":"2607_CR20","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nm.3828","volume":"21","author":"C Bonner","year":"2015","unstructured":"Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21:512\u20137.","journal-title":"Nat Med"},{"key":"2607_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.mehy.2018.02.025","volume":"114","author":"FM Finucane","year":"2018","unstructured":"Finucane FM. SGLT2 inhibitor-induced euglycaemic diabetic ketoacidosis may be due to abrupt, severe and transient impaired glucose sensing in susceptible individuals with a hitherto unrecognised beta cell SGLT variant. Med Hypotheses. 2018;114:11\u20132.","journal-title":"Med Hypotheses"},{"key":"2607_CR22","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/dme.12700","volume":"32","author":"E Laugesen","year":"2015","unstructured":"Laugesen E, \u00d8stergaard JA, Leslie RDG. Latent autoimmune diabetes of the adult: current knowledge and uncertainty. Diabet Med. 2015;32:843\u201352.","journal-title":"Diabet Med"},{"key":"2607_CR23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2337\/diab.42.2.359","volume":"42","author":"T Tuomi","year":"1993","unstructured":"Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes. 1993;42:359\u201362.","journal-title":"Diabetes"},{"key":"2607_CR24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/dmrr.503","volume":"21","author":"Z Zhou","year":"2005","unstructured":"Zhou Z, Li X, Huan G, et al. Rosiglitazone combined with insulin preserves islet \u03b2 cell function in adult-onset latent autoimmune diabetes (LADA). Diabetes Metab Res Rev. 2005;21:203\u20138.","journal-title":"Diabetes Metab Res Rev"},{"key":"2607_CR25","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1046\/j.1365-2265.2000.00983.x","volume":"52","author":"G Gambelunghe","year":"2000","unstructured":"Gambelunghe G, Forini F, Laureti S, et al. Increased risk for endocrine autoimmunity in Italian type\u00a02 diabetic patients with GAD65 autoantibodies. Clin Endocrinol. 2000;52:565\u201373.","journal-title":"Clin Endocrinol"},{"key":"2607_CR26","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.2337\/dc15-1251","volume":"38","author":"N Erondu","year":"2015","unstructured":"Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type\u00a02 diabetes clinical program. Diabetes Care. 2015;38:1680\u20136.","journal-title":"Diabetes Care"},{"key":"2607_CR27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/jdi.12401","volume":"7","author":"W Ogawa","year":"2016","unstructured":"Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig. 2016;7:135\u20138.","journal-title":"J Diabetes Investig"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02607-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-020-02607-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02607-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T04:55:09Z","timestamp":1613278509000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-020-02607-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,14]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2607"],"URL":"https:\/\/doi.org\/10.1186\/s13256-020-02607-2","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,14]]},"assertion":[{"value":"10 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Informed consent to participate in the study was obtained from the patient in accordance with the Helsinki convention.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}